Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577227 | 0.90 | TSHR (0.74) | DRD4TSHRPOLBHSD17B10ABCB1 | |
| SCHEMBL7999064 | 0.83 | DRD4 (0.86) | DRD4TSHRPOLBHSD17B10ABCB1 | |
| SCHEMBL12577241 | 0.82 | DRD4 (0.84) | DRD4TSHRPOLBABCB1GAA | |
| SCHEMBL2021188 | 0.81 | KCNH2 (0.81) | TSHRHSD17B10ABCB1KCNH2KMT2A | |
| SCHEMBL2014909 | 0.81 | KCNH2 (0.81) | TSHRHSD17B10ABCB1KCNH2KMT2A | |
| SCHEMBL2014914 | 0.81 | KCNH2 (0.81) | TSHRHSD17B10ABCB1KCNH2KMT2A | |
| SCHEMBL2021951 | 0.81 | TSHR (0.59) | TSHRPOLBHSD17B10ABCB1GAA | |
| SCHEMBL2023333 | 0.81 | TSHR (0.59) | TSHRPOLBHSD17B10ABCB1GAA | |
| SCHEMBL2021955 | 0.81 | TSHR (0.59) | TSHRPOLBHSD17B10ABCB1GAA | |
| SCHEMBL15586458 | 0.81 | DRD4 (0.57) | DRD4TSHRHSD17B10ABCB1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | DRD4 264/4885TSHR 407/4885POLB 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.